Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
GRECO-2: A Randomized, Phase II Study of Stereotactic Body Radiation Therapy SBRT in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I
NCTID: NCT03816358
Principal Investigator:
Anup Kasi
Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas.
Study Type: Treatment
Phase: II
NCTID: NCT02595424
Principal Investigator:
Anup Kasi
A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma EPIC
Study Type: Treatment
Phase: II
NCTID: NCT05915351
Principal Investigator:
Anup Kasi
BAY 1895344 Plus Topoisomerase-1 Top1 Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma SCLC, Poorly Differentiated Neuroendocrine Carcinoma PD-NEC and Pancreatic Adenocarcinoma PDA
PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields Ttfields, 150khz Concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: III
NCTID: NCT03377491
Principal Investigator:
Anup Kasi
A Phase 1/2 Study of M3814 Peposertib in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I/II
NCTID: NCT04172532
Principal Investigator:
Anup Kasi
A Phase II Study of 9-ING-41 GSK-3? Combined with Retifanlimab plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients with Advanced Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma with Molecular Correlates
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Study Type: Treatment
Phase: II
NCTID: NCT04858334
Principal Investigator:
Anup Kasi